Alcoholic liver disease

PRODIGY BIOTECH ENTERS INTO A PARTNERSHIP AGREEMENT WITH LEADING CANCER CENTER TO ADVANCE PRODUCTS TO IMPROVE OUTCOMES IN PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

Retrieved on: 
Tuesday, February 6, 2024
MSK, Partnership, Mortality, Alcoholic hepatitis, Research, MD, Therapy, Disease, Patient, IND, Graft-versus-host disease, Alcoholic liver disease, Immunoglobulin Y, Assistant, Drug development, Doctor of Philosophy, SAB, Dysbiosis, Gastrointestinal tract, Bloodstream infections, Cancer, Pharmaceutical industry

The accelerator program launch was announced at the MSK Life Sciences Innovation Summit in New York City on January 26, 2024.

Key Points: 
  • The accelerator program launch was announced at the MSK Life Sciences Innovation Summit in New York City on January 26, 2024.
  • Prodigy and Memorial Sloan Kettering Cancer Center (MSK) will co-develop a product targeting Enterococcus sp.
  • to treat microbial dysbiosis in patients undergoing allogenic hematopoietic stem cell transplantation.
  • February 6, 2024 – Prodigy and MSK have entered into a sponsored research agreement through the MSK Therapeutics Accelerator program to evaluate Prodigy’s product candidate for the improvement of outcomes in patients undergoing allogenic hematopoietic stem cell transplantation (allo-HCT).

Non-Alcoholic Steatohepatitis Treatment Drug Market In Japan is Expected to Showcase Impressive Growth by 2032 | DelveInsight

Retrieved on: 
Wednesday, January 17, 2024
Obesity, Merck & Co., MRI, LAS, Weight loss, Fatty liver disease, Type 2 diabetes, Magnetic resonance imaging, Insulin resistance, NASH, FFAR4, Liver, Liver disease, Diabetes, Alcoholic liver disease, Therapy, Hypertension, PPAR, Eli Lilly and Company, Gilead Sciences, Chronic pain, Disease, Inflammation, FASN, AstraZeneca, Novo Nordisk, FXR, Prevalence, CCR5, FGF, Physical examination, Weakness, Bronchial thermoplasty, Cilofexor, Metabolic syndrome, Mitsubishi Tanabe Pharma, Development, NAFLD, Risk, Fibrosis, Fatigue, Dyslipidemia, USD, Non-alcoholic fatty liver disease, Merck, Pharmaceutical industry

LAS VEGAS, Jan. 17, 2024 /PRNewswire/ -- DelveInsight's Non-Alcoholic Steatohepatitis Market Insights report includes a comprehensive understanding of current treatment practices, non-alcoholic steatohepatitis emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into Japan.

Key Points: 
  • LAS VEGAS, Jan. 17, 2024 /PRNewswire/ -- DelveInsight's Non-Alcoholic Steatohepatitis Market Insights report includes a comprehensive understanding of current treatment practices, non-alcoholic steatohepatitis emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into Japan.
  • According to DelveInsight's analysis, the market size for NASH reached USD 200 million in 2022 in Japan and is expected to grow with a significant CAGR by 2032.
  • DelveInsight's analysis reveals that the overall diagnosed prevalent population of NASH in Japan was reported as 2.5 million in 2022.
  • Among the forecasted emerging therapies, MGL-3196 (Resmetirom) is expected to capture the highest market in Japan by 2032.

Non-Alcoholic Steatohepatitis Treatment Drug Market In Japan is Expected to Showcase Impressive Growth by 2032 | DelveInsight

Retrieved on: 
Wednesday, January 17, 2024
Obesity, Merck & Co., MRI, LAS, Weight loss, Fatty liver disease, Type 2 diabetes, Magnetic resonance imaging, Insulin resistance, NASH, FFAR4, Liver, Liver disease, Diabetes, Alcoholic liver disease, Therapy, Hypertension, PPAR, Eli Lilly and Company, Gilead Sciences, Chronic pain, Disease, Inflammation, FASN, AstraZeneca, Novo Nordisk, FXR, Prevalence, CCR5, FGF, Physical examination, Weakness, Bronchial thermoplasty, Cilofexor, Metabolic syndrome, Mitsubishi Tanabe Pharma, Development, NAFLD, Risk, Fibrosis, Fatigue, Dyslipidemia, USD, Non-alcoholic fatty liver disease, Merck, Pharmaceutical industry

LAS VEGAS, Jan. 17, 2024 /PRNewswire/ -- DelveInsight's Non-Alcoholic Steatohepatitis Market Insights report includes a comprehensive understanding of current treatment practices, non-alcoholic steatohepatitis emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into Japan.

Key Points: 
  • LAS VEGAS, Jan. 17, 2024 /PRNewswire/ -- DelveInsight's Non-Alcoholic Steatohepatitis Market Insights report includes a comprehensive understanding of current treatment practices, non-alcoholic steatohepatitis emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into Japan.
  • According to DelveInsight's analysis, the market size for NASH reached USD 200 million in 2022 in Japan and is expected to grow with a significant CAGR by 2032.
  • DelveInsight's analysis reveals that the overall diagnosed prevalent population of NASH in Japan was reported as 2.5 million in 2022.
  • Among the forecasted emerging therapies, MGL-3196 (Resmetirom) is expected to capture the highest market in Japan by 2032.

Increasing Wages Will Lead to Healthier Work and Healthier Workers

Retrieved on: 
Wednesday, November 29, 2023
Life expectancy, Social epidemiology, Depression, Conditional sentence, Alcoholic liver disease, Mortality, Cardiovascular disease, Health, CVD, Opioid overdose, Dietary supplement, Nursing

LOS ANGELES, Nov. 29, 2023 /PRNewswire/ -- The Healthy Work Campaign applauds California for leading the way in 2023 to ensure fair, living wages for healthcare and fast-food workers.

Key Points: 
  • LOS ANGELES, Nov. 29, 2023 /PRNewswire/ -- The Healthy Work Campaign applauds California for leading the way in 2023 to ensure fair, living wages for healthcare and fast-food workers.
  • California has recognized that, due to wage stagnation and inflation, the living standard of low-income workers has been in decline for many years.
  • The Healthy Work Campaign has reported previously about the contribution of poor working conditions (including low wages) to the health of workers, especially those without a 4-year college degree, which includes fast-food workers and some healthcare support workers .
  • The Healthy Work Campaign urges other states to follow California's lead, to improve economic justice and the health of low-income workers throughout the U.S.

Hillstream Enters into an Exclusive Option Agreement to Acquire a Clinical Stage Asset for Chronic Pruritis

Retrieved on: 
Monday, September 11, 2023
Hepatitis, Mouth, Ascending cholangitis, Hepatology, Liver disease, PBC, Biotechnology, Atopic dermatitis, US, Primary biliary cholangitis, Patient, Liver, Cheek, Alcoholic liver disease, IND, Chronic kidney disease, Skin, Pharmaceutical industry, Hillstream loach

BRIDGEWATER, N.J., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (Nasdaq: HILS) ("Hillstream" or the "Company"), a biotechnology company developing therapeutic candidates targeting drug resistant and devastating cancer announces an exclusive option agreement to acquire a clinical stage asset, AV104, with a recently approved IND. AV104 has a dual mechanism of action by affecting multiple receptors, known to suppress chronic, debilitating pruritis or “uncontrollable itching”. The Company intends to first seek approval in an orphan disease for the treatment of moderate to severe cholestatic pruritis in patients with primary biliary cholangitis (PBC), a rare form of liver disease with no known cure in which more than 70% of patients suffer from chronic pruritis.

Key Points: 
  • AV104 has a dual mechanism of action by affecting multiple receptors, known to suppress chronic, debilitating pruritis or “uncontrollable itching”.
  • When the itch circuitry is imbalanced in diseased conditions, pharmacological intervention can help suppress this phenomenon which occurs in patients suffering from chronic pruritis.
  • Chronic pruritis is significant in liver diseases as well as chronic kidney diseases, hemodialysis and atopic dermatitis.
  • “This exclusive option allows the company to bring a clinical-stage asset into the organization as we shift into a patient-focused biotechnology organization.

Ocean Biomedical (NASDAQ: OCEA) Announces New Patent for Anti-Fibrosis Discovery with Allowance in Alcoholic Liver Disease and Multiple Fibrotic Conditions, Leading Causes of Death in the U.S.

Retrieved on: 
Tuesday, August 29, 2023
Patent, Human, Ocean Biomedical, NASH, RI, United States Patent and Trademark Office, Lupus, Asbestosis, Pulmonary fibrosis, Fibrosis, HPS, EPA, Connective tissue, Silicosis, Hermansky–Pudlak syndrome, Fatty liver disease, IPF, Alcoholic liver disease, Idiopathic pulmonary fibrosis, Rheumatoid arthritis, Scleroderma, Pharmaceutical industry, MD

Providence, RI, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA) announced today that the United States Patent and Trademark Office has issued a patent covering Ocean’s anti-Chitinase 1 small molecule candidate.

Key Points: 
  • Patent granted for use in IPF, HPS, alcoholic liver disease, nonalcoholic steatohepatitis (NASH), and scleroderma.
  • Providence, RI, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA ) announced today that the United States Patent and Trademark Office has issued a patent covering Ocean’s anti-Chitinase 1 small molecule candidate.
  • Targeted diseases include alcoholic liver disease, idiopathic pulmonary fibrosis (IPF), scleroderma, nonalcoholic steatohepatitis (NASH), and Hermansky-Pudlak Syndrome (HPS), a rare disease that currently has no known treatments.
  • Ocean’s approach has shown an 85%–90% reduction in collagen accumulation in four different IPF and HPS pulmonary fibrosis animal models.

Ocean Biomedical (NASDAQ: OCEA) Provides Latest Updates on its Broad Programs in Malaria, Fibrosis, and Multiple Cancers

Retrieved on: 
Thursday, August 10, 2023
Idiopathic disease, Melanoma, Idiopathic pulmonary fibrosis, Experiment, Doctor of Philosophy, Development, Patent, MD, Patient, Hermansky–Pudlak syndrome, Breast cancer, Brain, Prostate cancer, Malaria, Therapy, Climate, NASH, RI, Skin cancer, Research, Glioblastoma, Pulmonary fibrosis, Fatty liver disease, Response evaluation criteria in solid tumors, IPF, Death, Alcoholic liver disease, Monoclonal antibody, Kidney cancer, Lung cancer, Extension, Treatment of lung cancer, Messenger, Fibrosis, Science, Biomedicine, Cancer, Parasitism, Ovarian cancer, CHI3L1, Q&A, Lung, HPS, World Health Organization, Scleroderma, Medical device, Pharmaceutical industry, Vaccine, Medical imaging, Ocean Biomedical

Providence, RI, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), a biopharma company working to accelerate the development of compelling discoveries from top research scientists, shared today an update on its broad range of promising programs in malaria, fibrosis, and multiple cancers.

Key Points: 
  • In addition to the multi-pronged cancer program, the Company is advancing a novel malaria vaccine candidate and a companion malaria drug program.
  • The Company is also working to advance a much-needed pulmonary fibrosis treatment candidate to raise the standard of care available to patients with pulmonary fibrosis.
  • “Our team is simultaneously targeting several major cancer pathways,” said Dr. Jack A. Elias, a Scientific Co-founder of Ocean Biomedical.
  • Similarly, malaria and the cancers we are targeting are not adequately addressed by the current therapeutics because of efficacy or side effect shortcomings.

Ocean Biomedical, Inc. Joins the Russell 2000® Index

Retrieved on: 
Tuesday, June 27, 2023
Momentum, Executive, Ocean Biomedical, Therapy, RI, FTSE Russell, Malaria, Lung cancer, Research, Russell Indexes, Glioblastoma, Russell, Fibrosis, CFO, Growth, IPF, Alcoholic liver disease, Idiopathic pulmonary fibrosis, Prostate cancer, Pharmaceutical industry, Cryptocurrency

Providence, RI, June 27, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA) announced today that as part of the annual reconstitution of the Russell stock indexes, the Company has been included in the Russell 2000® Index and the broad-market Russell 3000® Index, which became effective on Monday, June 26, 2023.

Key Points: 
  • Ocean Biomedical’s Inclusion in the Russell 2000® Index and Russell 3000® Index Builds Momentum for Cutting Edge Therapeutic Programs Targeting Multiple Cancers, Fibrotic Diseases, and Malaria
    Providence, RI, June 27, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA ) announced today that as part of the annual reconstitution of the Russell stock indexes, the Company has been included in the Russell 2000® Index and the broad-market Russell 3000® Index, which became effective on Monday, June 26, 2023.
  • “We are thrilled to announce our inclusion in the esteemed Russell 2000® Index, a renowned benchmark for small-cap stocks,” exclaimed Elizabeth Ng, CEO of Ocean Biomedical.
  • Membership in the Russell 3000® Index means automatic inclusion in the large-cap Russell 1000® Index or small-cap Russell 2000® Index, as well as in the appropriate growth and value style indexes.
  • For more information on the Russell 2000® Index and the Russell U.S. Indexes Reconstitution, visit the “Russell Reconstitution” section on the FTSE Russell website .

Ocean Biomedical (NASDAQ: OCEA) Extends Patent Rights for Breakthrough Idiopathic Pulmonary Fibrosis Discovery To Europe

Retrieved on: 
Friday, June 23, 2023
Molecule, Ocean Biomedical, Idiopathic pulmonary fibrosis, NASH, Hermansky–Pudlak syndrome, RI, Guidelines for Examination in the European Patent Office, Non-alcoholic fatty liver disease, Alcoholic liver disease, Pulmonary fibrosis, Fibrosis, EPA, HPS, MD, European Patent Convention, Syndrome, IPF, Pharmaceutical industry, Patent, Scleroderma

Providence, RI, June 23, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA) announced today that Scientific Co-founder Dr. Jack A. Elias, MD received notice from the European Patent Office of its intention to grant European patent rights for Methods and Compositions relating to the treatment of fibrosis using Ocean’s anti-Chitinase 1 small molecule candidate (“Small Molecule X”), a new target discovered by Dr. Elias that appears to be a major factor in controlling—and inhibiting—fibrosis progression.

Key Points: 
  • Patent notice extends global coverage for breakthrough discovery, with potential for treating Idiopathic Pulmonary Fibrosis (IPF) and other fibrotic diseases, including Scleroderma, Nonalcoholic Steatohepatitis (NASH), Hermansky-Pudlak syndrome (HPS), and Alcoholic Liver Disease.
  • Providence, RI, June 23, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA ) announced today that Scientific Co-founder Dr. Jack A. Elias, MD received notice from the European Patent Office of its intention to grant European patent rights for Methods and Compositions relating to the treatment of fibrosis using Ocean’s anti-Chitinase 1 small molecule candidate (“Small Molecule X”), a new target discovered by Dr. Elias that appears to be a major factor in controlling—and inhibiting—fibrosis progression.
  • Ocean’s approach has shown an 85%–90% reduction in collagen accumulation in four “gold standard” IPF and HPS pulmonary fibrosis animal models.
  • This treatment approach is anticipated to be well-tolerated based on data from original (non-Ocean) clinical studies and recent EPA data.

Ocean Biomedical (NASDAQ: OCEA) Announces Share Price Target Increase to $17.63 by Fundamental Research Corp. on Positive Results from Independent Study Showing Glioblastoma Tumor Suppression, Received Patents, and Recent Financing

Retrieved on: 
Wednesday, June 21, 2023
Research report, NASH, Ocean Biomedical, Infection, FRC, Research, Projection, Fibrosis, Patent, Research fellow, Parasitism, FDA, Alcoholic liver disease, IND, News, Scleroderma, Malaria, Pharmaceutical industry

Since FRC’s initial report, Ocean Biomedical being granted two new U.S. patents, and one Brazilian patent, for drug and vaccine candidates targeting malaria and cancer treatment.

Key Points: 
  • Since FRC’s initial report, Ocean Biomedical being granted two new U.S. patents, and one Brazilian patent, for drug and vaccine candidates targeting malaria and cancer treatment.
  • OCF-203 also has potential to treat scleroderma (skin inflammation), alcoholic liver disease, and NASH (non-alcoholic liver damage).”
    Infectious Diseases.
  • A copy of Fundamental Research Corp.’s full analyst report can be obtained directly from the firm.
  • All reports on OCEA prepared by analysts represent the views of such analysts and are not necessarily those of OCEA.